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Abstract
Background: Many patients at high risk of cardiovascular diseases are managed and monitored in
general practice. Recommendations for cardiovascular risk management, including lifestyle change,
are clearly described in the Dutch national guideline. Although lifestyle interventions, such as advice
on diet, physical exercise, smoking and alcohol, have moderate, but potentially relevant effects in
these patients, adherence to lifestyle advice in general practice is not optimal. The IMPALA study
intends to improve adherence to lifestyle advice by involving patients in decision making on
cardiovascular prevention by nurse-led clinics. The aim of this paper is to describe the design and
methods of a study to evaluate an intervention aimed at involving patients in cardiovascular risk
management.
Methods:  A cluster-randomised controlled trial in 20 general practices, 10 practices in the
intervention arm and 10 in the control arm, starting on October 2005. A total of 720 patients
without existing cardiovascular diseases but eligible for cardiovascular risk assessment will be
recruited.
In both arms, the general practitioners and nurses will be trained to apply the national guideline for
cardiovascular risk management. Nurses in the intervention arm will receive an extended training
in risk assessment, risk communication, the use of a decision aid and adapted motivational
interviewing. This communication technique will be used to support the shared decision-making
process about risk reduction. The intervention comprises 2 consultations and 1 follow-up
telephone call. The nurses in the control arm will give usual care after the risk estimation, according
to the national guideline.
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Primary outcome measures are self-reported adherence to lifestyle advice and drug treatment.
Secondary outcome measures are the patients' perception of risk and their motivation to change
their behaviour. The measurements will take place at baseline and after 12 and 52 weeks. Clinical
endpoints will not be measured, but the absolute 10-year risk of cardiovascular events will be
estimated for each patient from medical records at baseline and after 1 year.
Discussion: The combined use of risk communication, a decision aid and motivational interviewing
to enhance patient involvement in decision making is an innovative aspect of the intervention.
Trial registration: Current Controlled Trials ISRCTN51556722
Background
Despite a decreasing trend in mortality from cardiovascu-
lar diseases, these diseases are still the main cause of mor-
tality in the Western world, and cardiovascular diseases
cause 33% of all deaths in the Netherlands [1,2].
Unhealthy lifestyles, rather than medical conditions or
genetic predisposition, are thought to be the most impor-
tant and modifiable causes of the majority of deaths from
CVD [3,4]. It is estimated that 30% of all new cases of cor-
onary heart disease and 19% of all strokes are caused by
smoking, while other lifestyle factors, such as diet, also
play an important role in the development of CVD [5].
Preventive guidelines on CVD and diabetes recommend
medical treatment for patients at high risk. In addition,
they recommend patient education and counselling on
smoking, diet, physical exercise and alcohol consumption
for large groups of patients with moderately increased
risk. The Dutch multi-disciplinary guidelines for cardio-
vascular risk management (CVRM) also underline the
importance of a healthy lifestyle for the prevention of
CVD. The core of the guideline consists of a risk table for
the assessment of the 10-year risk of CVD, showing the
various risk factors which can be reduced [6].
Lifestyle changing programmes for the prevention of CVD
have shown moderate but significant effects and have
proved to be cost-effective [7-12]. However, changing life-
style is very difficult for people. The public's adherence to
lifestyle advice and medication varies between 20 and
90%, with most estimates converging around 50%
[13,14]. Improving this adherence requires effective inter-
ventions, comprising educational and behavioural com-
ponents [15]. Adherence seems to be influenced by health
beliefs such as risk perception, perceived benefits and dis-
advantages of treatment and self-efficacy, as well as stage
of change and communication problems with physicians
[16-18]. Each high-risk individual can usually choose
between several options for risk reduction. Since patients
seek treatment approaches which are manageable and in
their view effective, their preferences can differ considera-
bly from those of the professionals. Many people prefer
lifestyle change to drug treatment, but beliefs about treat-
ments differ between physicians and patients, making it
difficult to achieve consensus about the best treatment.
True dialogue is required if patients' preferences are to be
used to make decisions effectively [19,20].
The IMPALA (IMproving Patient Adherence to Lifestyle
Advice) project builds on earlier work at our department.
Van der Weijden evaluated the effect of implementation
of the Dutch cholesterol guideline for cholesterol among
6 GPs [21]. This resulted in negative findings, without
improvement in underuse or overuse of statins. It
appeared that the mismatch between the guideline and
the patients' expectations or preferences was one of the
main barriers to change. Van Steenkiste tried to involve
patients in the decision-making process for cardiovascular
risk reduction by implementing a decision support tool
and using a risk table. He found no effect on the GPs' per-
formance and a minimal effect in terms of the patients'
cardiovascular risk reduction. From process evaluation it
appeared that the patients had not been optimally
exposed to the decision support tool. It was recom-
mended delegating CVRM to a practice nurse and extend-
ing the implementation for involving the patient in
CVRM [22]. For the IMPALA study, an innovative nurse-
led implementation strategy was developed, comprising
key elements of risk assessment, risk communication, a
decision aid, and adapted motivational interviewing. The
IMPALA study investigates whether patients' adherence to
medication and lifestyle advice can be increased through
patient involvement and shared decision making [20].
Many of the patients with moderate to high CVD risk, but
without existing CVD, are monitored in primary care.
According to the guideline for CVRM, prevention of CVD,
especially patient education and support in lifestyle
change, seems to be a good task to delegate to a practice
nurse in primary care [6]. The number of general practices
employing a qualified practice nurse is increasing. These
practice nurses mainly perform standardised tasks for
patients with chronic diseases like asthma, hypertension
or diabetes. The nurse works under the supervision of a
general practitioner.BMC Health Services Research 2008, 8:9 http://www.biomedcentral.com/1472-6963/8/9
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Most patients have difficulty understanding CVD risks
[22,23]. Perception of risks tends to be inaccurate and
people find it difficult to interpret and act upon risk infor-
mation. The format (framing) in which risk information
is presented affects people's perception of risks and their
decisions. For instance, information framed in terms of
relative risk or loss framing is more persuasive than fram-
ing in terms of absolute risk or gain framing. This has been
reported for both doctors and patients [24-29]. Risk com-
munication should include weighing up the risks and
benefits of a treatment choice, and should address the
patient's perception of the probability of an event as well
as the importance of the event for that individual [26].
Increasing people's competence to understand their actual
cardiovascular risk, the pros and cons of possible treat-
ments and their options for modifying the risk, as well as
the competence to clarify their own values and to become
involved in the decisions, seems to lead to better-
informed decisions [18,30-32]. Information on treatment
options and their advantages and disadvantages is ideally
integrated in a well-designed and validated decision aid
[33], which can help both physicians or practice nurses
and patients in the process of making the best choice for
the management of CVD risk. It may help the unaware
high-risk person to agree with risk-reducing strategies and
the 'worried-well' low-risk person to agree with non-indi-
cation for risk-reducing drugs. There is increasing evi-
dence that decision aids increase patients' active
involvement in decision making [32]. However, assessing
the 10-year risk of CVD and informing the patient about
different options for risk reduction is only one step in a
process of lifestyle change. Additional components are
needed to reach a shared decision which the patient is
motivated to adhere to. Professionals will have to facili-
tate the process, and to communicate in a patient-oriented
way.
The motivational interviewing method seems a good tool,
in addition to the use of the risk chart and the decision
aid, to achieve shared decision making [32]. Adapted
motivational interviewing has been used [34] to set the
agenda of consultations together with patients, to assess
patients' motivations for behaviour change and build
motivation for healthy behaviours, and to achieve goal
setting and specific action plans. Motivational interview-
ing is an approach that can be described by its four basic
principles: expressing empathy, developing discrepancy,
rolling with resistance and supporting self-efficacy [34-
36]. The consultations for the IMPALA intervention will
be held in the spirit of these basic principles, and an
adapted form of motivational interviewing will be used.
Since it is possible that the two consultations will only be
the first step in a long process of preventive support, a tel-
ephone consultation is added to the intervention as the
initial step towards follow-up. Telephone counselling by
practice nurses seems a valuable approach for adequate
follow-up support [37,38].
The impact of the IMPALA intervention will be assessed by
means of various evaluations. First, the effect of the nurse-
led intervention on the adherence to lifestyle advice will
be examined and compared with that of nurse-led usual
care.
A more detailed understanding of the components of the
intervention which are successful while others fail to
change behaviour requires gaining insight into the 'black
box' of the intervention. Prospective recording is a
method to evaluate the intervention process in terms of
materials used, themes of communication, and time
needed. Studying interactions by means of audiotaped
recordings can assess the use of motivational interviewing
and the principles of shared decision making. This infor-
mation will be used to examine factors that moderate or
mediate intervention effects. Since attitudes play an
important role in adapting to a new way of working [39],
it is important to evaluate the experiences of the general
practitioners and practice nurses with the intervention, to
determine the feasibility of a wider implementation of the
intervention.
The patients in the intervention arm will probably notice
the attempts to promote patient involvement and the
changes in the relationship between health professional
and patient and in the communication during the consul-
tations. In an earlier community-oriented and individual-
oriented prevention project for cardiovascular diseases in
the Dutch province of Limburg, frictions and irritations
were found among both health advisors and patients in
the consultations [40]. In this project, the research agenda
had determined a large part of the agenda setting of the
prevention activities, and the options for risk reduction
were limited to certain themes. In the context of CVD pre-
vention, a deliberative model of the relationship between
physician or practice nurse and patient is preferable to
other models of the physician-patient relationship [41].
In this model, the aim of physician-patient interaction is
to help the patient determine and choose the best health-
related values that can be achieved in the clinical situa-
tion. The role of the physician is that of a teacher or a
friend, engaging the patient in a dialogue on the best
course of action. The IMPALA project will involve inter-
views in which patients will be asked about their experi-
ences with and opinions about the IMPALA intervention,
so that this can be evaluated from an ethical perspective.
We hypothesise that the intervention will modify patients'
adherence to lifestyle advice, but the intervention may
also improve the healthcare process implemented by GPsBMC Health Services Research 2008, 8:9 http://www.biomedcentral.com/1472-6963/8/9
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and practice nurses and hence the amount of time and
effort required from the professionals [42]. Since this
study will determine both the effects and the costs of the
implementation of the nurse-led intervention an eco-
nomic evaluation of the intervention is planned to com-
pare the cost-effectiveness ratio in the intervention group
with that in the control group.
Research questions
1. What is the effect of our nurse-led intervention for
CVRM, including risk communication, a decision aid and
adapted motivational interviewing, on patients' adher-
ence to lifestyle advice? [Effect evaluation]
2. To what extent do the nurses adhere to the intervention
for CVRM and decision support, and what are the experi-
ences and opinions of GPs and practice nurses about this
strategy? [Process evaluation]
3. How do patients experience the nurse-led intervention
for CVRM, and what is the ethical value of the interven-
tion? [Ethical evaluation]
4. What is the incremental cost-effectiveness ratio of the
nurse-led intervention for CVRM and decision support
compared to usual care by a practice nurse? [Economic
evaluation]
Methods
Design
The IMPALA study is a cluster-randomised controlled trial
involving 20 general practices and 720 patients in the
Netherlands. An independent statistician will perform a
central block randomisation. Practices will be randomly
allocated, 10 practices to the intervention group and 10
practices to the control group, after stratification into 4
geographical regions. Assessments will be made at the
inclusion of the patients in the study, at 12 weeks and at
52 weeks. A flowchart of the study is shown in Figure 1.
Ethical approval and informed consent
The Medical Ethical Committee of the University of Maas-
tricht has granted ethical approval. The trial is registered as
ISRCTN51556722 [43].
An information sheet will be given to all eligible patients.
Patients will be informed on all aspects of the project by
means of written information and personally at the inclu-
sion. The privacy of the participating patients is protected,
and all data will be coded and processed anonymously. It
will be made clear in the informed consent form that each
patient can terminate his or her participation the study at
any moment. Patients will be asked to sign the informed
consent form, and return this to Maastricht University to
allow further contact regarding the research.
General practices
Inclusion criteria for the general practices are that they
have to employ a practice nurse and work with electronic
patient records. Practices will be invited by letter to partic-
ipate in the trial. Addresses will be obtained from the
NIVEL (Netherlands Institute for Health Services
Research) database. If a practice expresses interest, it will
be visited by members of the project team for further
information and explanation about the study. Non-
responding GPs will be reminded after 1 month, by
renewed postal invitation. The general practices will be
located in the central and southern parts of the Nether-
lands. In the Netherlands, all patients are obliged to be
registered with a general practice.
Participants
The inclusion criteria for participants are based on the
Dutch guideline for CVRM. According to the guideline,
the following patients are eligible for a cardiovascular risk
assessment:
Especially patients
• who have high blood pressure (≥ 140 mmHg) or are
already being treated for it; and/or
￿ who have high total cholesterol (≥ 6.5 mmol/l) or
already being treated for it; and/or
￿ who are smokers (men ≥ 50 years, women ≥ 55 years);
and/or
￿ who have diabetes.
In addition, patients:
￿ who have positive family history of CVD; and/or
￿ who have visible obesity.
Patients with existing cardiovascular diseases, patients at
high risk based on familial hypercholesterolaemia only
and patients who are primarily managed in secondary
care (e.g. by cardiologists or internists or in rehabilitation
programmes) will be excluded from the study. This is a
clinical approach to primary prevention. We will not
manipulate the process of identifying potential high-risk
patients other than by informing the GPs about the inclu-
sion criteria, to stimulate usual strategies for case finding,
either by the GPs during consultation hours or by the
nurses inviting high-risk patients from available patient
records. To facilitate the inclusion process, the GPs and
practice nurses will receive a chart stand, with the inclu-
sion criteria which they can place on their desk.BMC Health Services Research 2008, 8:9 http://www.biomedcentral.com/1472-6963/8/9
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Sample size calculation and feasibility of recruitment
The study will be powered on outcomes on patient behav-
iour to detect an absolute 52-week, post-intervention,
between-group difference of 15% (50 – 65%) in patients'
self reported adherence to life-style advice on smoking,
diet, alcohol and physical exercise (alpha = 0.05, power =
0.80). The figure of 50% represents the average adherence
by patients with chronic diseases [13]. The power calcula-
tion for clustered data analysis assumes an intra-class cor-
relation coefficient (ICC) of 0.04. ICC values in earlier
trials among general practitioners were 0.06 [44] and 0.03
[45]. Since we expect that the nurses will perform well in
terms of adhering to the working protocol, we expect a
lower ICC, with a maximum of 0.04. Thus, the within-
cluster variance will be almost equal to the between-clus-
ter variance. This implies that 600 patients are needed
(300 per group) at 52 weeks. It is our intention that a total
of 720 patients will be recruited by the GPs or practice
nurses, to compensate for an expected 15% loss to follow-
up (in an earlier trial by van Steenkiste, 87% of the
included patients responded at the 6-month follow-up
[45]). It should be possible to prospectively recruit 720
patients (36 per practice) in 6 months, as Dutch general
practices each have 100–150 of these patients, who visit
the practice at least once a year for regular monitoring.
Intervention
The GPs will delegate to the practice nurses the tasks of
risk assessment, patient education and counselling. The
practice nurses will be equipped to roll out an interven-
tion comprising (1) risk assessment, (2) risk communica-
tion, (3) distribution of a decision aid and (4)
motivational interviewing. These strategies will be distrib-
uted over two consultations and a follow-up telephone
call (see Figure 2). Each consultation will take about 15
minutes, with a maximum of 30 minutes. The duration of
Flowchart of the IMPALA study Figure 1
Flowchart of the IMPALA study.
    
Time line  Measurements 
October 2005 
Intervention Usual  Care 
13 practices  12 practices 
January 2006 
T0 -  Questionnaire 
- CVD risk  
   registered by 
   nurse 
T1 -  Questionnaire 
     and pedometer 
     sent to home 
     address 
 
 T2  -  Questionnaire 
     sent to home 
     address 
   -  CVD  risk 
       extracted from 
       medical file 
       by nurse 
Inclusion of 360 patients 
 
Inclusion of 360 patients 
 
Randomisation 
Usual care Intervention 
Extensive training  Short training
Recruitment: 
25 practices BMC Health Services Research 2008, 8:9 http://www.biomedcentral.com/1472-6963/8/9
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Graphical depiction of intervention and measurements Figure 2
Graphical depiction of intervention and measurements. Graphical depiction of intervention and measurements 
(above), with legend (below). Squares represent fixed elements, e.g. objects and calculations. Circles represent activities that 
are flexible. Randomisation and measurements are shown in grey. This graphical method was proposed by Perera et al [76].
Time line  Intervention group  Control group 
Randomisation   
   
Baseline (T 0)     
Intervention 
 
First consultation 
 
Second consultation 
 
Telephone call 
  
     
12 weeks (T1)     
52 weeks (T2)     
A B A
C C E  D  D  E 
I H  F  F  G
J
K
L  L 
D  M D  M
D  D 
 
  Training (2 hours) of nurses in Dutch national guideline for cardiovascular risk management (CVRM) and in 
identification of patients for a risk assessment 
  Training (2 days) of nurses in risk communication, use of risk communication tool, handing over a decision aid 
and the use of adapted Motivational Interviewing 
  Recruitment of patients by GP or practice nurse 
  Completion of questionnaire by patient (At T0: will be handed over to patient by recruitment. At T1 and T2: will 
be sent to home address of patient) 
  Completion of informed consent form by patient (will be handed over to patient by recruitment)  
  Completion of cardiovascular risk profile of patient by nurse in first consultation 
  Nurse will explain cardiovascular risk to patient 
  Nurse will hand over decision aid and will invite patient for second consultation 
  Nurse will apply usual care 
  In a second consultation (approx. 2 weeks after first consultation) the nurse will discuss the risk and possible 
options for risk reduction with the patient by means of adapted motivational interviewing 
  Nurse will discuss in telephone call (approx. 2 weeks after second consultation) the possible options for risk 
reduction by means of adapted motivational interviewing 
  After the consultations, the nurses will complete the recording form about the consultations (for process 
evaluation) and about the patient’s risk profile and will send it to researchers 
  Step counter: counts the total number of steps per day, during 3 days (will be sent to home address of patient) 
A
B
C
D 
E 
F 
G
H 
I
J
K
L 
M 
 BMC Health Services Research 2008, 8:9 http://www.biomedcentral.com/1472-6963/8/9
Page 7 of 15
(page number not for citation purposes)
the phone call will vary, but is not meant to last over 10
minutes.
(1) Risk assessment
The assessment of the 10-year risk of CVD will be done
with the help of the risk table from the Dutch guideline on
CVRM, published and produced in 2006 by the Dutch
Institute for Health Care Improvement (CBO), in close
collaboration with the Dutch College of General Practi-
tioners (NHG), and has also been approved by the rele-
vant clinical specialist groups, such as cardiologists [6,46].
The risk table is derived form the European Score risk
table [46], adapted to the Dutch situation. The cardiovas-
cular risk of patients with diabetes will be estimated with
a table derived from the UKPDS risk engine [47].
(2) Graphical risk communication tool
The risk communication tool is a sheet showing graphical
information that the nurse can use to communicate the
risk more explicitly to the patient. It has been suggested
that risks can be more understood by patients if different
ways are used to present them, such as natural frequen-
cies, positive and negative framing and a population
chart. It has also been recommended to explain the uncer-
tainty to the patient [48]. The practice nurse can visualise
the total risk, as well as the relative contributions of mod-
ifiable risk factors to the total risk. Both absolute and rel-
ative risks will be framed and depicted in numbers (by
natural frequencies) and in graphs (by population dia-
gram). The risk communication tool was developed in a
pilot study. A practice nurse from a general practice that
will not be included in the main study administered the
tool to 8 patients, who were interviewed about the differ-
ent graphical risk presentations, clarity, language and lay-
out of the tool. The tool was then adapted on the basis of
the outcomes of these interviews.
(3) Decision aid
An earlier version of the decision aid was tested in an RCT
by Van Steenkiste [45]. The 16-page decision aid (in bro-
chure form) informs patients about their absolute 10-year
CVD risk, both verbally and numerically, and presents
options for risk reduction, such as use of medication or
lifestyle changes. The risk table from the guideline on
CVRM is also made available to the patients. The brochure
will be handed over by the nurse to the patient at the end
of the first consultation. The patient is expected to read the
decision aid at home and return to the nurse to discuss
what should or should not be done.
(4) Adapted Motivational Interviewing
In the second consultation, the nurse will apply adapted
motivational interviewing to support the patient in the
process of decision making about CVRM. The first step is
to set the agenda for the consultation, together with the
patient [36]. The patient will chose one or more key items
in CVRM (smoking, physical exercise, dietary behaviour,
alcohol consumption and adherence to medical treat-
ment) in this agenda setting. After this, the nurse will
assess the patient's current behaviour and motivation for
change, by rating and exploring importance and confi-
dence with respect to the chosen key items. If there is a
need and sufficient motivation for change regarding one
or more items, the nurse will consult with the patient to
select one item as the goal for behaviour change. The
nurse will inform the patient about local opportunities for
individual or group support in lifestyle change that tie in
with the patient's goal, if appropriate.
Follow-up
Little is known about the number of consultations featur-
ing motivational interviewing that is needed to optimise
the effect in terms of behaviour change, as regards inten-
sity and frequency but the assumption is that a second
motivational interviewing consultation will probably
increase the effect of the intervention [49]. Therefore, the
nurse will apply the same adapted motivational interview-
ing in the follow-up telephone call (lasting a maximum of
10 minutes). The nurse will assess the patient's actual
motivations for change, ask for their experiences with spe-
cific actions (if applicable) and continue to work on
importance and confidence.
The intervention can be embedded in a long-term treat-
ment approach. After the telephone consultation, the
nurse and the patient decide whether and what continua-
tion is needed, for example some extra consultations to
support the lifestyle change or regular monitoring of
weight or blood pressure.
Training
The nurses will receive a two-day training, outside the
practice. The GPs will only be invited for the part of the
training that concerns the new guideline on CVRM.
Homework about risk assessment and motivational inter-
viewing will be sent to the nurses with the request to study
the materials, which should take them about 4 hours. The
two-day training consists of the following elements:
- Introduction 1: hour
- Outlining the multifaceted strategy and various aspects
of the study: 1 hour
- Information on the new guidelines for CVRM, on the
assessment of the individual 10-year risk of CVD by
means of vignettes, on the recommendations for lifestyle
counselling and risk reduction by medication such as
blood pressure or cholesterol lowering drugs: 1.5 hours.BMC Health Services Research 2008, 8:9 http://www.biomedcentral.com/1472-6963/8/9
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- Communicating the risk to patients using a risk commu-
nication tool, and disseminating the decision aid to
patients: 2 hours.
- Specific training in the adapted motivational interview-
ing technique that is to be used to discuss the decision aid
with patients after it has been studied by them at home;
involving patients in decision making and goal setting: 7
hours.
Afterwards:
- After completing the training course, the nurses will
audiotape 3 consultations and will receive written feed-
back from the researchers on their communication tech-
niques.
Usual care
The practice nurses for the control group will receive only
a short training on the new guideline for CVRM and will
be instructed to administer usual care consistent with cur-
rent guidelines. Usual care depends on patients' risk pro-
file and their preferences for risk reduction. In normal
situations, when blood pressure and cholesterol levels are
sufficiently controlled, the guidelines recommend one
follow-up consultation a year. In order to keep the nurses
in the control arm motivated, the extended training in risk
communication and motivational interviewing will be
offered after the inclusion period of the trial and after the
short-term measurement at 12 weeks. To protect the con-
trast between the intervention group and the control
group, the nurses for the control group have to 'promise'
not to administer the intervention to the included
patients before their last measurement (52 weeks). The
nurses will receive a list of the included patients in their
practice, specifying the exact moment of the last measure-
ment for each patient.
Effect evaluation
The aim of the effect evaluation is to examine the patients'
adherence to lifestyle advice. The research question is:
What is the effect of a nurse-led intervention for CVRM,
including risk communication, a decision aid and adapted
motivational interviewing, on patients' adherence to lifestyle
advice?
Variables and measurements
Primary outcome measures are the patients' adherence to
lifestyle advice and drug treatment. The current state-of-
the-art in measurement of adherence behaviour is a multi-
method approach that combines feasible self-reporting
and reasonably objective measures [50,13]. Specific
behaviours relating to smoking, saturated fat intake, fruit
and vegetable consumption, physical exercise, alcohol use
and use of cardiovascular medication will be reported by
patients, using validated self-reported questionnaires. For
a detailed overview of the outcome measures, question-
naires and types of variables, see Tables 1 and 2. We will
use pedometers at 12 weeks to measure physical exercise
[51], although we recognise that this measurement may
itself increase activity levels. Pedometers are reasonably
accurate for walking activities [50]. Patients will be
instructed to measure during 3 days in one week [52].
Body mass index will be measured as a proxy measure of
healthy diet and exercise.
Clinical endpoints will not be assessed, but the absolute
risk of cardiovascular events in 10 years will be calculated
using the risk table from the Dutch guideline for CVRM
[6]. For patients with diabetes, the UK PDS risk engine
will be used. Calculation of the patients' absolute risk of
Table 1: Primary outcome measures
Outcome measure Instrument (Number of items, reference, validated yes/no) Analysis
Fruit and Vegetables 8 items; [66]; Validated questionnaire mean sum score; proportion meeting 
recommendations
Fat intake 35 items; [67] Validated questionnaire mean sum score
Physical exercise 15 items; [68, 69]; validated questionnaire, modified Dutch 
version of the CHAMPS has not been validated.
mean; proportion meeting recommendations
Smoking 2 items; [70]; Validated questionnaire proportion smoking
Alcohol consumption 2 items; [71]; validated questionnaire proportion meeting recommendations
Adherence to medical treatment 5 items; (MARS) [72], not validated mean
Cholesterol level [6] Measured by nurse mean score, proportion above 
recommendation
Blood pressure [6] Measured by nurse mean score, proportion above 
recommendation
Body Mass Index [6] Measured by nurse mean score, proportion above 
recommendation
10-year risk of CVD based on patient's sex, age, blood pressure, cholesterol and 
smoking behaviour; [73];
mean score, proportion above 
recommendationBMC Health Services Research 2008, 8:9 http://www.biomedcentral.com/1472-6963/8/9
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cardiovascular events in 10 years, which is a proxy meas-
ure of actual health gain, will be based on known and
available determinants: diabetes, age, sex, smoking, blood
cholesterol level and systolic blood pressure. After one
year, the risk of CVD will also be estimated, by deriving
data on the risk factors from medical records in general
practice. Since there is (according to the CVRM guide-
lines) no need to assess someone's cholesterol level annu-
ally if this level is acceptable, it is possible that some of the
data used for the estimation will not be recent (with a
maximum of one year).
Secondary outcome measures are the perception of the
patients' own health behaviour, risk perception, anxiety,
self-efficacy, importance of behaviour change, satisfaction
with communication and confidence in the decision that
has been made. Other factors that will be recorded include
patient demographic factors (age, sex, education) and
medical characteristics. See Table 2 for secondary out-
comes.
Timing of measurements
Measurements will take place at three moments (see Fig-
ures 1 and 2):
- T0 (baseline): The patients will receive the first question-
naire from their GP or practice nurse at the time they are
invited to enrol in the study. The nurse will send a post-
age-paid postcard with the patient number to the
researchers at Maastricht University (UM). Before a
patient visits the practice for the first consultation, he/she
will complete the first questionnaire and an informed
consent form. After each consultation, the nurse will
record on a standardised form some patient characteristics
like age, sex, blood pressure, cholesterol level, glucose
level, height, weight and the occurrence of CVD in the
family (yes or no).
- T1 (12 weeks): A second questionnaire and the pedom-
eter will be sent to the patient's home address.
- T2 (52 weeks): The final questionnaire will be sent to the
patient's home address. The nurses will be asked to record
data regarding the biological parameters (cholesterol
level, blood pressure, glucose, diabetes yes/no) from the
most recent patient contact.
All the questionnaires, the informed consent form and a
form to record the number of steps that were made are to
be sent to the researchers in a postage-paid envelope after
completion. Materials (questionnaires, informed consent
form, recording forms for nurses, initial postcard) will
carry a unique patient number.
Data analysis
Since it is not possible to restrict our study to one primary
outcome for all patients beforehand, the study will exam-
ine 6 different lifestyle changes: smoking, physical exer-
cise, fat intake, fruit, vegetables and alcohol.
To assess the difference in primary outcomes between the
arms, the arms will first be compared in terms of changes
in the specific lifestyle issues, independent of the targets
chosen by the intervention patients. We will use a T test
for continuing variables and a χ2 test for dichotomous var-
iables.
A second analysis of primary outcomes is a multilevel
regression analysis (using SPSS and MLwin), which uses
adherence to the primary outcomes of lifestyle change as
the dependent variables and group allocation and pre-
intervention scores as independent variables. Additional
independent variables will be included in the model, such
as patient characteristics (age, sex, anxiety and risk of
CVD). Additional regression analyses will focus on the
effect at T2.
The third analysis involves constructing a simple stand-
ardised overall adherence score for the six lifestyle items,
which expresses to what extent, on average, patients
achieved the behaviour change goals of the national rec-
ommendations for a healthy lifestyle. The score of the
intervention group will be compared with that of the con-
trol group.
Finally, the reduction in the 10-year risk of CVD will be
analysed for differences between the two arms. The risk of
CVD will be analysed with a multilevel regression analy-
Table 2: Secondary outcome measures
Outcome measure Instrument (Number of items, reference, validated yes/no) Analysis
Perception of own health behavior 1 item for each primary lifestyle outcome; question with 5-point scale mean
Attitude towards behaviour change 1 item for each primary lifestyle outcome; question with 5-point scale mean
Self-efficacy about specific behaviour change 1 item for each primary lifestyle; question with 5-point scale mean
Risk perception 2 items; [74] mean
Anxiety 2 items; [45] proportion
Satisfaction with communication and confidence in decision 20 items; (COMRADE) [75] meanBMC Health Services Research 2008, 8:9 http://www.biomedcentral.com/1472-6963/8/9
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sis, which uses the risk at 52 weeks as the dependent vari-
able and group allocation and pre-intervention risk as
independent variables.
The secondary outcomes will also be analysed for the dif-
ferences between the arms, using a T test for continuing
variables and a χ2 test for dichotomous variables. We also
intend to use a multilevel regression analysis (using
MLwin) which uses e.g. self-efficacy and attitudes at T1 as
the dependent variables and group allocation and pre-
intervention scores as independent variables. Additional
independent variables, such as patient characteristics (age,
gender, risk of CVD and socio-economic status), will also
be included in the model. Additional regression analyses
will focus on the effect at T2. Further analyses for sub-
groups of patients are also possible.
In addition, we will describe the personal targets of the
patients in the intervention arm, which will be recorded
by the nurses.
Process evaluation
The purpose of the process evaluation is to establish
actual exposure to the intervention as it was intended, and
to examine which components of the intervention were
successful and which ones were not. The research ques-
tion is: To what extent do the nurses adhere to the intervention
for CVRM and decision support, and what are the experiences
and opinions of the GPs and nurses with regard to this inter-
vention?
Variables and measurements
Data on the nurses' actual adherence to the components
of the strategy will be gathered by the nurses themselves
by means of prospective self-reports. Nurses will use a
short standardised questionnaire after each consultation
to record which components of the intervention have
been applied. Each item will be scored as a done/not done
binary variable (see Table 3 for the key intervention fea-
tures that will be scored). On top of this, each nurse will
be instructed to audiotape 3 consultations, namely one of
the initial ones and two later on in the trial. In addition to
this quantitative approach to process evaluation, we will
also use a qualitative approach, in that the nurses will be
invited to a focus group interview to discuss their percep-
tion of determinants of success and failure. The variation
in the effects at the patient and nurse levels will also be
discussed. Finally, a subgroup of GPs will be invited for
face-to-face interviews about their opinion on the inter-
vention. The sample will include practices with successful
as well as less successful patient inclusion. The focus
group and the interviews will be moderated by an experi-
enced GP, who is not a member of the research group.
Data analyses
The self-reported done/not done components of the inter-
vention will be presented as the proportion of the consul-
tations in which the component has been applied. The
audiotaped consultations in the intervention group will
be scored with the IMPALA Practice nurses Scoring list
(IPS), a scoring list based on the IMPALA training pro-
gramme and on other existing scoring lists [53,54], to
determine the extent to which the motivational interview-
ing technique was implemented. The consultations will
be scored with the OPTION instrument to measure to
what extent practice nurses have involved patients in the
decision-making process [55,56]. The interviews with the
nurses and the GPs will be transcribed and coded by three
persons, using a coding list. Differences of opinion will be
discussed until agreement is reached.
Ethical evaluation
The ethical evaluation will use interviews with individual
patients regarding their opinions about and experiences
with the consultations of the intervention, to evaluate the
Table 3: Key features of the intervention for quantitative process 
evaluation
1st consultation Nurse explains the risk to the patient by means of 
the risk communication tool.
Nurse hands over the risk communication tool.
Nurse hands over decision aid booklet + risk 
communication tool (to consider at home).
2nd consultation Patient shows up for second consultation. If 
patients cancel, they are asked for the reason
Nurse uses motivational interviewing; sets agenda 
with the help of an agenda-setting chart, 
establishes importance and confidence, explores 
importance and builds confidence by asking the 
patient questions.
Which options for risk reduction were discussed 
during the consultation?
Nurse guides the patient in formulating the main 
personal goal for lifestyle change (if applicable).
When medication is prescribed: has the nurse 
consulted the GP?
Which other health education materials were 
used during the consultation?
Telephone call The telephone call takes place. If patients cancel, 
they are asked for the reason
Nurse uses motivational interviewing; sets agenda 
with the help of an agenda-setting chart; 
establishes importance and confidence, explores 
importance and builds confidence by asking the 
patient questions.
Which options for risk reduction were discussed 
during the telephone call?
Nurse guides the patient in formulating the main 
personal goal for lifestyle change (if applicable).
Extra items Time needed per patient contact.
Time needed to discuss patients with GP.
Appointment for follow-up consultation after the 
telephone call, if necessary.BMC Health Services Research 2008, 8:9 http://www.biomedcentral.com/1472-6963/8/9
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intervention in the light of the models of physician-
patient relationship by Emanuel and Emanuel [41].
The research question is: How do patients experience the
nurse-led intervention for CVRM, and what is the ethical value
of the intervention?
Variables and measurements
At least 16 patients of 4 practices will be invited by the
nurses to participate in an interview. The 4 nurses imple-
menting the intervention most satisfactorily (judging
from the audiotaped consultations), will be asked to
invite a variety of patients in terms of sex, 10-year risk of
CVD and the course of the consultations.
The interviews will be 'open', in that the interviewer will
try to access the patient's personal story. The interviews
will be held in the diagnostic style, and will characterised
by an interested and personal approach [57]. The inter-
views will be based on a list of themes to ensure that all
relevant items are brought up during the discussion (see
Table 4). All interviews will be audiotaped, with the
patients' permission, and transcribed later. The interviews
will be done by an experienced junior social scientist, who
is not a member of the research group.
Data analysis
The interviews will be analysed by the constant compara-
tive method as described in grounded theory [58]. Inter-
views will be coded and the codes will be grouped,
compared and categorised.
Economic evaluation
The aim of the economic evaluation is to assess the costs
of the IMPALA intervention. The research question is:
What is the incremental cost-effectiveness ratio of a nurse-led
intervention for CVRM and decision support compared to usual
care by a practice nurse?
Measurements and variables
The use of CVD-related health care resources will be meas-
ured by means of questions about health care use (pre-
scribed medication, tests, referrals, numbers of contacts)
over a 3-month period before completion. Costs of CVD
events will be estimated from the literature and/or analy-
ses of aggregate data sources (hospital information sys-
tems). Cost calculation will be based on real prices or on
unit prices from the Dutch guideline for cost calculation
[59]. Quality of life will be measured with the SF-36, a val-
idated questionnaire [60]. The costs of implementing the
intervention will be recorded by the researchers.
Timing of measurements
The questions for the economic evaluation will be incor-
porated in the questionnaires of the effect evaluation at
T0, T1 and T2.
Data analyses
The economic evaluation will be a cost-effectiveness
study. We expect no differences in short-term societal
costs because the improvements in lifestyle will mainly
have effects in the long term. Therefore, the analyses will
use a health care sector perspective, and will thus also
show the expected costs and consequences per general
practice. The base case involves calculation of an incre-
mental cost-effectiveness ratio (ICER) of patient involve-
ment as regards the estimated reduction of CVD events in
10 years on the basis of T2 data [61]. Quality improve-
ment cost-effectiveness will be combined with treatment
cost-effectiveness according to the Mason model [62,63].
Table 4: Interview themes for ethical evaluation
1. Expectations before 
the consultations 
about:
the role of the patient (e.g. active/passive);
the role of the practice nurse (e.g. guiding, 
informative, clarifying, reflecting);
the gain from the consultations (e.g. 
information, becoming aware, getting 
attention, reflection and a motivated 
decision, guiding towards a decision).
2. Experiences with 
the consultations
Understanding the situation.
What had the patient picked up from the 
consultations?
What was the role of the tools in this 
understanding?
How was the patient involved in the 
consultations?
Active participation in the discussion.
Personal involvement in the topic.
Contribution to the decisions that were 
made.
How did the nurse approach the patient (e.g. 
attentive, open to the patient's opinion, 
steering, informative, giving his/her own 
view)?
What was the impact of the consultation
for the patient's personal life and well-
being;
as regards clear decisions, goals and a 
plan?
The tools of the intervention
What did the tools mean to the patient?
Was anything missing from the 
consultations?
3. Preferences for 
future consultations:
about the patient's role;
about role of the practice nurse;
about the significance of the consultation. 
When is a consultation successful?BMC Health Services Research 2008, 8:9 http://www.biomedcentral.com/1472-6963/8/9
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Cost differences between the intervention and control
groups will be statistically tested by calculating the 2.5 –
97.5 percentile intervals of the bootstrapped resamples.
In addition, we will use a long-term economic evaluation
to explicitly reveal the relationship between the CVD risk
reduction achieved and the required investment for the
implementation strategy. For this purpose, a Markov
health state transition model will be developed, with a
first-order Monte Carlo simulation in which each patient
goes through the model individually. The cycle length will
be one year. The time horizon of the analysis is the full
lifetime of the population. Costs and benefits will be dis-
counted according to national guidelines (4%). A one-
way sensitivity analysis will be used to establish the indi-
vidual effects of model parameters on the results of the
analysis. The model parameters will be varied across a
plausible range. Parameter uncertainty will be further
tested using probabilistic sensitivity analysis, which takes
into account the fact that some combinations of factors
are more likely than others [64].
Discussion
The intervention that will be evaluated in this trial is char-
acterised by some innovative aspects. Firstly, not much is
known yet on the effect of the combined use of risk com-
munication, a decision aid and motivational interviewing
to enhance patient involvement in decision making. Sec-
ondly, delegation of such tasks to a practice nurse is a new
approach in the Netherlands, and is in line with current
changes in general practice care processes in this country
(increasing practice sizes and multidisciplinary health
centres employing nurses).
A factorial or multiple-arm RCT design would have been
optimal from the methodological perspective, and could
shed light on the effectiveness of the individual ingredi-
ents of this multifaceted intervention in terms of the pri-
mary outcomes. However, this would have blown up the
design to include multiple trial arms and large numbers of
practices and patients, and turn it into an unfeasible
experiment. The analyses of our secondary outcomes will
probably shed light on the effectiveness of individual
ingredients of the intervention. In some of the secondary
outcomes, such as risk perception, the relation with indi-
vidual ingredients, such as risk communication, seems
one-dimensional. The way in which risk communication,
the decision aid and motivational interviewing are
applied during the trial will be documented in a process
evaluation, which will give further information on the
impact of intervention components on the main out-
comes.
The pilot version of the risk communication tool included
a Paling scale, a scale to compare the risk of cardiovascular
risk with other risks of life. After the pilot test, we decided
to remove the Paling scale because it was too difficult
according to the patients who received the risk communi-
cation tool in this pilot test.
When we developed the decision aid, the IPDAS criteria
for decision aids had not yet been published [65], but the
decision aid does comply with most of the these criteria,
namely using a systematic development process, provid-
ing information about options, presenting probabilities,
disclosing conflicts of interests and using plain language.
On the other hand, our decision aid does not fully meet
the criteria on balancing the presentation of options, clar-
ifying and expressing values, and guiding/coaching in
deliberation and communication, although patients will
be invited to deliberate about the decision making, and
the motivational interviewing in our strategy is meant to
help patients clarify and express values.
Cardiovascular risk is not the primary outcome of the
effect evaluation because this is a pragmatic trial about the
implementation of the Dutch national guideline for
CVRM. To reduce the burden of data collection for the
health care professionals, we will ask them to collect only
the data they need for the risk estimations. There is no
budget for additional data collection outside routine prac-
tice by the researchers.
Although we intended to use more objective measures for
the primary outcomes of the effect evaluation, this was
precluded by logistic and financial reasons. The relatively
inexpensive breath carbon monoxide test is not very sen-
sitive, and the more reliable urine cotinine marker is
expensive and difficult from a logistic point of view. A
biomarker for fruit and vegetables, such as carotene meas-
urement, is expensive, and no simple biomarker for alco-
hol is available. The influence of information bias
resulting from subjective self-reports is reduced in the data
analysis, which takes the pre-intervention scores (which
have the same information bias) into account. Although
self-reported smoking status is known to be biased, meas-
urement of a biological marker has various disadvantages.
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